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Abstract
Background: Semenogelins (SEMGs) are major components of human seminal vesicle secretions. Due to SEMG’s
sperm-motility inhibitor, a significant negative correlation between sperm motility and the proportion of SEMG-bound
spermatozoa (SEMG+) was found in asthenozoospermic patients. SEMGs also show intrinsic inhibitory capability for sperm
capacitation; however, studies on actual clinical specimens have not been conducted.
Methods: To reveal the relationship between SEMGs and the fertilizing capacity of sperm from male infertile
patients who are not restricted to asthenozoospermia, we measured the proportion of SEMG+ in the spermatozoa of
142 male infertile patients. The pregnancy outcomes in partners of these patients were retrospectively analyzed using
questionnaires.
Results: Among examined semen parameters, only the total SEMG-unbound sperm count showed a tendency to be
different between the spontaneous pregnancy or intra-uterine-insemination-pregnancy groups and in-vitro-fertilization-
or intracytoplasmic-sperm-injection-pregnancy groups. It was elevated in the former group, which includes patients
who used in vivo fertilization.
Conclusions: The total SEMG-unbound sperm count would be a relevant parameter for in vivo fertilization. This result
suggests that SEMGs inhibit ectopic capacitation before sperm reach the fertilization site and that the number of total
SEMG-unbound sperm is a parameter directly linked to the possibility of in vivo fertilization.
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Résumé
Contexte: Les séménogélines (SEMG) sont des composantes principales des sécrétions des vésicules séminales
humaines. En raison de la présence sur SEMG d’un inhibiteur de la mobilité des spermatozoïdes, une corrélation
significative a été rapportée entre la mobilité des spermatozoïdes et le pourcentage de spermatozoïdes liés à SEMG
chez des patients asthénozoospermiques. Les SEMG possèdent aussi une capacité intrinsèque d’inhibition de la
capacitation; aucune étude n’a cependant été réalisée sur des échantillons de sperme utilisés en pratique clinique
quotidienne.
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Matériel et méthodes: De façon à mettre en évidence une relation entre les SEMG et la capacité fécondante de
spermatozoïdes d’hommes inféconds qui ne soient pas seulement des patients asthénozoospermiques, nous avons
mesuré la proportion de spermatozoïdes SEMG+ (liés à SEMG) chez 142 patients inféconds. L’issue des grossesses
chez les partenaires de ces patients a été rétrospectivement analysée à partir de questionnaires.
Résultats: Parmi les paramètres spermatiques analysés, seul le nombre total de spermatozoïdes non liées à SEMG
montre une tendance à être différent entre le groupe de grossesses obtenues spontanément ou par insémination
intra-utérine et le groupe de grossesses obtenues par fécondation in vitro ou injection intra-cytoplasmique d’un
spermatozoïde. Ce nombre total était élevé dans le premier groupe qui incluait des patients utilisant une fécondation
in vivo.
Conclusions: Le nombre total de spermatozoïdes non liés à SEMG pourrait être un paramètre pertinent pour
la fécondation in vivo. Ces résultats suggèrent que les SEMG inhibent la capacitation ectopique avant que les
spermatozoïdes n’atteignent le site de fécondation, et que le nombre total de spermatozoïdes non liés à SEMG est. un
paramètre directement lié à la possibilité de fécondation in vivo.
Mots-clés: Protéine plasmatique séminale, Infécondité masculine, Séménogélines, IIU, FIV, ICSI, Issues de grossesses
Background
Globally, approximately 15% of couples of reproductive-
ages do not achieve pregnancy within 1 year of regular un-
protected sexual intercourse and seek fertility assessment
[1]. Among these couples, eventually 5% remain unwill-
ingly childless. Male infertility-associated factor, together
with abnormal semen parameters, contributes to 50% of
involuntarily childlessness in couples. Semen analysis is
the most widely used biomarker to predict the male fertil-
ity potential. Its result gives a wide array of information
on the functional status of the whole male sex system,
such as hormone axis, seminiferous tubules, epididymis,
and accessory sex glands. On the other hand, as it is a
complex test, semen analysis should ideally be conducted
in andrology laboratories by experienced technicians in
the presence of internal and external quality controls; val-
idation of test systems; and quality assurance during all
testing processes, some of which are often difficult to im-
plement in practice [2]. These difficulties often prevent
comparative studies of multicenter data. Additionally,
their ability to predict male fertility potential has been
questioned, unless the parameters truly are at extremely
low levels. For example, among infertile men, semen ana-
lysis results are normal in up to 40% of cases [3].
To overcome these insufficiencies of routine semen
analysis for diagnosis, specialized andrology tests have
emerged to account for sperm dysfunction. Formerly,
particularly before the advent of intracytoplasmic sperm
injection (ICSI), tests that assessed antisperm antibodies,
sperm hyperactivation, and acrosome reaction; sperm
binding; and penetration to the human zona pellucida
were used to investigate males with unexplained infertil-
ity [4]. These tests hold the capability to reveal problems
that may exist in each step of conventional in vitro
fertilization (IVF), and help to predict the fertilizing po-
tential of sperm in this procedure. However, treatments
for many of these potential issues are often extremely
difficult or do not exist. Furthermore, the efficacy of
assisted reproductive techniques (ART), particularly
ICSI, is essentially unaffected by these problems; thus,
clinical usage of these tests is highly restricted. Based on
the increased knowledge regarding the molecular mech-
anisms that regulate sperm function, oxidative stress
levels and nuclear DNA integrity in the determination of
the functional competence of human spermatozoa have
been emphasized. These parameters seem to better cor-
relate with male fertility than does standard semen ana-
lysis, and tests to measure them have become clinically
available. However, to be used routinely, these tests
should meet the following requirements, including
standardization of protocols, validation of results in lar-
ger trials, and cost-effectiveness analyses.
Semenogelins (SEMGs) are major components of hu-
man seminal vesicle secretions and are comprised of two
closely-related proteins: SEMG 1 and 2 [5]. These two
proteins and their degradation byproducts hold a variety
of physiological roles [6]. Ejaculated semen immediately
turns into a gelatinous meshwork, in which cross-linking
SEMGs are major components and sperms are entrapped.
During liquefaction, SEMGs are degraded into low mo-
lecular mass proteins by a prostate-specific antigen (PSA),
and sperms start to move [7]. However, it was shown that
seminal hyperviscosity had no relation to the degree of
SEMG degradation [8], thereby indicating that SEMGs do
not inhibit sperm motility through seminal viscosity. One
of the fragments of the degraded SEMGs, a seminal
plasma motility inhibitor (SPMI), inhibits the motility of
both demembranated spermatozoa and intact spermato-
zoa. SEMGs have an inhibitory effect on the acrosome re-
action induced by fetal cord serum ultrafiltrate. At
present, SEMGs and their degradation peptides are con-
sidered decapacitation factors that prevent human sperm
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capacitation. The mechanism underlying these physio-
logical roles of SEMGs and their degradation fragments
are still unclear. Interestingly, our group recently reported
the association between SEMGs and spermatozoa in infer-
tile men with asthenozoospermia [9].
Based on the clinical relevance of SEMGs to male fac-
tor infertility and their putative physiologic role, we hy-
pothesized that SEMGs might be targets for developing
new sperm function tests that can guide couples with
male factor infertility to select the most appropriate
treatment. In this study, we examined the condition of
SEMGs bound to sperm from infertile patients and
retrospectively analyzed the pregnancy outcomes of
these patients’ partners using questionnaires. These re-
sults can provide information on the new sperm func-
tion tests using SEMGs by indicating whether they are




One hundred and forty-two cases of male infertile pa-
tients who had visited the reproduction center of the
International University of Health and Welfare Hospital
(IUHW) from August 2012 to March 2013 were in-
cluded in this study. All infertile couples had undergone
treatments at IUHW. The policy of infertility treatment
at IUHW, according to the semen condition of the male
partner, is as follows: for normal findings or in the case
of mild oligozoospermia and /or asthenozoospermia,
natural pregnancy or intra-uterine insemination (IUI)
using the timing method are considered as the first
choice, followed by a “step-up” to IVF/ICSI when preg-
nancy is not achieved; for severe oligozoospermia and/or
asthenozoospermia, IVF/ICSI is conducted from the be-
ginning. Furthermore, partners of patients with psycho-
genic erectile dysfunction or intravaginal ejaculation
disorder are initially treated with IUI.
As part of this study, a physical examination and evalu-
ation of male infertility was performed for each subject.
During the period of follow-up until the end of 2014, we
sent questionnaires to all male infertile patients to obtain
data of pregnancy outcomes and collected the answers
from 96 of them, which were accompanied by semen ana-
lysis data and SEMG+ measurements taken at the first
medical examination. Of these 96 partners of patients, 36
were confirmed to achieve pregnancy by any means of IUI,
IVF, ICSI or spontaneous conception (“Pregnancy group”),
while remaining 60 partners of patients kept unpregnant
by the end of the follow-up period (“Non-pregnancy
group”). Thirteen normal healthy male subjects whose
wives were in the twentieth week or later of spontaneous
pregnancy and who received prenatal examinations in the
hospital were recruited to participate as “control” subjects
in this study after it was confirmed that they did not have
any types of intrascrotum abnormality, including varico-
cele. Informed consent was obtained from all participants
for the use of the data obtained from a physical examin-
ation, semen, and blood samples. The study protocol was
approved by the Institutional Review Board at IUHW and
at Toin University of Yokohama in Japan.
Semen analysis and hormone measurements
Semen samples were obtained via masturbation follow-
ing sexual abstinence for at least 48 h. Specimens were
allowed to liquefy for up to 1 h after ejaculation at room
temperature. Complete liquefaction was certified macro-
scopically according to the WHO manual by confirming
that the semen becomes homogeneous and quite watery,
and only small areas of coagulation remain. Manual
semen analysis was performed according to the WHO
manual to determine semen volume and sperm concen-
tration. For analysis of sperm motility, the SMAS™
(Ditect, Tokyo, Japan) system was used. Additionally, the
serum levels of luteinizing hormone (LH), follicle-
stimulating hormone (FSH), and testosterone (T) were
measured using a chemiluminescent immunoassay (SRL
Inc., Tokyo, Japan). The reference ranges for LH, FSH,
and T were 0.79–5.72 mIU/ml, 2.00–8.30 mIU/ml, and
1.31–8.71 ng/ml, respectively. The intra-assay coefficient
of variation (CV) for LH, FSH, and T were 3.03%, 3.74%,
and 5.13%, respectively. The inter-assay CV for LH, FSH,
and T were 1.84%, 0.43%, and 3.99%, respectively.
Indirect immunofluorescence assay
Following semen analysis, semen samples were refriger-
ated until use. Pretreatment and staining methods were
the same as described in the previous study [9]. Briefly,
semen samples were layered onto 65% Percoll/HEPES-
buffered saline (HBS; 130 mM NaCl, 4 mM KCl, 1 mM,
CaCl2, 0.5 mM MgCl2, 14 mM fructose and 10 mM
HEPES, pH 8.0) and centrifuged at 1200 g for 30 min at
25 °C. The resulting pellet was fixed with 2% paraformal-
dehyde phosphate buffer, pH 7.4. The fixed sperm were
then washed twice with HBS, mixed with 25% block-Ace
(Dainippon Sumitomo Pharma, Osaka, Japan) and then
incubated at 37 °C for 1 h, then washed with HBS at
3300 g for 10 min at 25 °C. An aliquot of the washed
sperm was incubated with 1 μg/mL anti-seminal plasma
motility inhibitor (SPMI) mouse immunoglobulin G
(IgG) that recognized a part of the SPMI region (138–
154: GTQNPSQDSGNSPSGKG) of SEMG (monoclonal
antibody, previously described as anti-Sg antibody F11) or
mouse IgG isotype control (DAKO Japan, Tokyo, Japan)
at 37 °C for 1 h [10]. Sperm were then washed twice with
HBS at 3300 g for 10 min at 25 °C. Washed sperm were
incubated with Alexa 488-conjugated anti-mouse IgG
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(Molecular Probes, Eugene, OR, USA) at 37 °C for 1 h.
The samples were then analyzed using a flow cytometer.
Flow cytometric analysis
Flow cytometric analysis was performed as described in
the previous study [9]. Briefly, samples were analyzed
with flow cytometry using a Gallios™ flow cytometer
(Beckman Coulter, Tokyo, Japan) equipped with stand-
ard optics. For each cell, forward light scatter, orthog-
onal light scatter, and Alexa 488 (FL1) were evaluated
using the Kaluza® software (Beckman Coulter, Tokyo,
Japan). The sperm population of each sample was identi-
fied using the side scatter (SSC) and FL1 fluorescence
intensities. Debris was gated out by establishing a region
around the population of interest, based on FL1/ SSC 2-
dimensional histogram. Ten thousand spermatozoa per
sample were analyzed. The spermatozoa were labeled
with anti-SPMI mouse IgG (SEMG-positive spermato-
zoa) and positive and negative populations were deter-
mined by comparing the population of control staining
using mouse IgG isotype control, instead of the antibody
(Additional file 1: Figure S1). The proportion of SEMG-
positive spermatozoa (SEMG+) was then calculated by
dividing the number of labeled spermatozoa by the num-
ber of spermatozoa analyzed, and the proportion of
SEMG-negative spermatozoa (SEMG−) was determined
by subtracting the percentage of SEMG+ from 100.
Total SEMG- count was calculated using the proportion
of SEMG- and total sperm count.
Statistical analysis
Statistical analyses comparing mean values of each param-
eter for patients and control subjects were performed with
JMP software (version 10.0.0, SAS Institute Inc., Cary, NC,
USA) using Wilcoxon rank sum test. Additionally, the
Spearman’s rank correlation coefficient was applied be-
tween the results for the proportion of Sg + and the results
of standard semen analysis. Statistical analyses comparing
differences in the continuous variables were performed
with the “R” statistical software system (www.cran.r-projec-
t.org) [11] using analysis of variance, followed by Dunnett’s
test using the “multcomp” package [12].
Results
Parameters from SEMG-labeling analysis and other
parameters among infertile male patients
The clinical characteristics and proportions of SEMG+
and SEMG− were examined retrospectively (Table 1).
Statistically significant differences were observed be-
tween male infertile patients and control subjects re-
garding all the parameters explored, including the
proportion of SEMG+ (71.2 vs. 20.0%, P < 0.001). Not-
ably, the number of control subjects was small. This is a
reasonable result given that our control subjects were
men who were confirmed not to be infertile. The correl-
ation between the proportion of SEMG+ and the results
of standard semen analysis among male infertile patients
(Table 2) and control subjects (Additional file 2: Table S1)
was analyzed. A trend of negative correlation was ob-
served between the proportion of SEMG+ and sperm mo-
tility only in male infertile patients, though it was weak
(ρ = −0.23, P = 0.05), while no significant correlations
were observed between the proportion of SEMG+ and
sperm concentration, or between SEMG+ and sperm via-
bility. None of the other parameters such as age, serum T
level, serum FSH level, and/or serum LH level were sig-
nificantly correlated with the proportion of SEMG+ in
both infertile patients and in control subjects.
Relationship between SEMG-labeling analysis and
pregnancy outcomes
Next, we compared the pregnancy and non-pregnancy
groups in patients to check if there were any differences
in parameters. No parameters, including the proportion
of SEMG+/− and total SEMG+/− count, demonstrated
significant differences between the two groups (Table 3).
Then, we examined whether there were differences in
SEMG+/− and/or other parameters between the two
groups (pregnancy established with sperm passing
through the uterus and oviduct (spontaneous and IUI, in
vivo fertilization) versus pregnancy established without
sperm passage into the uterus (IVF or ICSI, in vitro
fertilization)), since SEMGs are considered to suppress
the process of ectopic capacitation in uterus and to be
removed from the surface of sperm in oviduct during in
vivo fertilization [13–15]. We compared the summed
data of spontaneous pregnancy and IUI to that of IVF
and ICSI (Table 4). The proportion of SEMG+/− and
total SEMG+ count also did not show a difference be-
tween these two groups; however, the total SEMG−
count in the IVF- or ICSI-pregnancy group tended to be
lower than in the spontaneous pregnancy or IUI-
pregnancy group (36.7 × 106 vs. 73.4 × 106, P = 0.06).
Discussion
Previously, our group reported the association between
SEMGs and spermatozoa in infertile men with astheno-
zoospermia [9]. A significant negative correlation was
found between sperm motility and the proportion (R = −
0.68) and intensity (R = − 0.38) of anti-SPMI labeling,
implying that the SPMI, and eventually SEMGs, binding
to the sperm surface might account for some disorders
in sperm motility that are observed in infertile men with
asthenozoospermia.
In this study, we expanded the pool of potential sub-
jects to include infertile patients whose infertility was
caused not only by asthenozoospermia but also by oligo-
zoospermia and normozoospermia (cryptogenic male
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infertility). We further explored the possibility of SEMGs
bound to spermatozoa being a predictor of infertility
treatment for such a variety of infertile patients in the
future. We confirmed a negative correlation between
sperm motility and the proportion of SEMG+ in this
study, although it was a comparatively weak correlation
since the subjects included in this study were not re-
stricted to those with asthenozoospermia (Table 2). For
this reason, one might assume that a normal subject
bears a lower proportion of SEMG+, since their sperm
motility is normal. However, this is not necessarily true
since the proportion of SEMG+ is often high, even in an
infertile subject whose sperm motility is normal. There-
fore, it is possible that the proportion of SEMG+ is an
indicator of normal fecundity of the spermatozoa inde-
pendently of their motility.
The proportion of SEMG+, as well as any other pa-
rameters, including sperm motility, did not show a sig-
nificant difference between the pregnancy and non-
pregnancy groups, which indicated that it might not be a
general predictor of ability to bear children in an infer-
tile subject. Naturally, the link between SEMGs and the
success of pregnancy requires further support. This is
because, in addition to factors associated with the male,
factors associated with the female, the fertilized egg, and
the early development of the embryo are all involved in
the success of pregnancy. To conduct an analysis while
considering these confounding factors, it is necessary to
further investigate increasing the number of specimens.
Next, based on the hypothesis that the condition of
SEMGs bound to spermatozoa differs between preg-
nancy achieved through IUI or spontaneous pregnancy
and that achieved through IVF or ICSI, we focused on
the result of 36 cases in which conception was achieved.
When the summed data of spontaneous pregnancy and
IUI was compared to the summed data of IVF and ICSI,
the total SEMG− count was apparently higher in the
former. Such a tendency was not observed in any of the
other parameters, including the proportion of SEMG+.
Although the precise molecular mechanism underlying
the controlling fertilizing capacity of sperm in vivo have
not been revealed, the role of SEMGs on sperm were
well studied and proved to control motility and capacita-
tion [8, 16–18]. Moreover, according to our analysis in
knockout mice, seminal vesicle secretion 2 (SVS2), an
orthologue of SEMGs, is essential for in vivo fertilization
[13]. SVS2 is thought to be a protector against spermi-
cidal agents in the uterus, and to be removed from the
Table 1 Clinical characteristics and the proportion of SEMG+ and SEMG− in subjects
Characteristics Patients (N = 142) Control (N = 13)
Mean ± SD Median Min-max Mean ± SD Median Min-max
Age (years) 36.5 ± 6.6 35.5 21–60 30.1 ± 4.1 29.5 25–36
Vol (mL) 4.25 ± 1.73 3.75 1.2–9.3 N/A N/A N/A
Conc (×106/mL) 50.6 ± 58.0 33.9 0.0004–400 76.8 ± 7.3 81.5 45.9–167.8
Mot (%) 27.5 ± 19.9 25.75 0–86.1 63.4 ± 2.1 61.05 50.8–86.6
TSC (×106/mL) 208.7 ± 19.8 143.5 0.003–1475 N/A N/A N/A
Viability (%) 55.76 ± 19.3 58.7 1.8–87.6 N/A N/A N/A
SEMG+ (%) 71.2 ± 20.2 73.5 12.2–99.2 20.0 ± 11.8 18.6 6.1–53.2
SEMG− (%) 28.8 ± 20.2 26.5 0.8–87.8 80.0 ± 11.8 81.4 46.8–93.9
SEMG+ SEMG-positive spermatozoa, SEMG− SEMG-negative spermatozoa; Patients: male infertile patients; Control: normal healthy male subjects with
pregnant wives





Mot (total sperm motility)
TSC (total sperm count)
Viability (sperm viability)
Table 2 Correlation between the proportion of SEMG+ and
standard semen analysis among male infertile patients
Characteristics Correlation coefficient (ρ) P value
Age (years) 0.00 0.986
Vol (mL) 0.02 0.838
Conc (×106/mL) −0.12 0.152
Mot (%) −0.23 0.005
TSC (×106/mL) −0.14 0.098
Viability (%) −0.13 0.134
FSH (mIU/mL) 0.13 0.135
LH (mIU /mL) 0.09 0.320
T (ng/dL) 0.00 0.985
ρ: Spearman’s rank correlation coefficient
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sperm’s surface after passing through the isthmus [14].
Coincidently, the removal of SVS2 induces the decrease
of cholesterol from the sperm membrane, thereby result-
ing in the ability of sperm to fertilize the egg [15]. The
data in this study indicate that a patient with a larger
number of spermatozoa with removed SEMGs can be
involved in a successful pregnancy via in vivo
fertilization. The removal of SEMGs from the surface of
spermatozoon under normal conditions allows for sperm
to fertilize an egg. Furthermore, the number of such
spermatozoa is important for in vivo fertilization.
While results from this study provide a minimum-
requirement analysis of the SEMGs bound to spermatozoa
and conventional semen analysis focused on pregnancy
outcomes, this study also provides the need for further
large-scale studies to establish diagnostic certainty. In
addition to this study having a small patient population, this
study has a limitation that the characteristics of the female
partners, such as age and oocyte quality, are not considered.
Pregnancy outcomes of a couple are usually strongly
affected by the condition of the female partner. Thus, it is
possible that the influence of male factors on pregnancy
outcomes is importantly obscured under such uncontrolled
conditions of the female. Surprisingly, SEMGs were found
to be potential biomarkers that can guide a couple to select
a suitable method of assisted reproductive technology. They
were also found to be particularly valuable for the decision
to use IVF or ICSI rather than IUI. Usually, natural preg-
nancy or IUI using the timing method are used in infertile
couples with no particular female factors when the male
partner is normozoospermic or mildly oligozoospermic or
asthenozoospermic. According to the findings of this study,
Table 3 Comparison between patients whose partners achieved pregnancy and those whose partners did not
Characteristics Pregnancy (N = 36) Non-pregnancy (N = 60) P value
Mean ± SD Median Min-max Mean ± SD Median Min-max
Age (years) 35 ± 5.8 34.5 21–48 37 ± 6.4 36 26–56 0.24
Vol (mL) 3.9 ± 1.4 3.6 1.2–8 4.0 ± 1.7 3.7 1.2–8.9 0.89
Conc (×106/mL) 49.7 ± 57.0 33.9 0.001–322.8 53.9 ± 68.8 34.8 0.0004–399.9 0.92
Mot (%) 28.8 ± 20.5 26.9 0–86.1 25.6 ± 18.8 24.65 0–66.4 0.43
TSC (×106/mL) 186.3 ± 196.3 145.1 0.005–839.3 279.8 ± 221.0 126.4 0.003–1475 0.89
Viability (%) 57.6 ± 14.8 57.4 21–84.2 55.5 ± 20.1 58.8 1.9–86.6 0.85
FSH (mIU/mL) 4.9 ± 2.7 4.6 1.6–16 5.2 ± 3.8 4.3 1.4–18.8 0.73
LH (mIU/mL) 3.5 ± 1.7 2.8 1.8–7.8 2.9 ± 1.5 2.6 1.3–9.6 0.08
T (ng/dL) 487.7 ± 171.4 480.3 124–1067 463.6 ± 166.6 448 167–834 0.51
SEMG+ (%) 73.9 ± 18.5 73.2 27.6–99 71.9 ± 19.8 73.8 12.2–96.9 0.70
SEMG- (%) 26.1 ± 18.5 26.8 26.8 28.1 ± 19.8 26.2 3.1–87.8 0.70
Total SEMG+ count (×106) 127.7 ± 121.6 101.5 0–548.0 144.8 ± 185.3 77.3 0–1075 0.83
Total SEMG− count (×106) 58.6 ± 96.4 28.7 0–430.2 76.2 ± 143.6 21.0 0.0002–821.5 0.90
Note that only 96 of 142 patients answered the questionnaires regarding pregnancy outcomes and were included in this analysis. Mean values of each parameter
for patients and control subjects were compared using Wilcoxon rank sum test
Table 4 Comparison within pregnancy groups
Characteristics SP + IUI (N = 20) IVF+ ICSI (N = 16) P value
Age (years) 35 ± 6.1 36 ± 5.5 0.44
Semen volume (mL) 4.0 ± 1.3 3.8 ± 1.4 0.74
Sperm concentration (×106/mL) 56.2 ± 67.0 41.7 ± 42.0 0.34
Sperm motility (%) 31.2 ± 22.3 25.8 ± 18.2 0.67
Sperm viability (%) 59.0 ± 12.9 55.7 ± 17.3 0.91
Total sperm count (×106) 203.6 ± 195.0 163.5 ± 199.4 0.32
Total motile sperm count (×106) 88.4 ± 158.2 65.0 ± 120.1 0.26
Total viable sperm count (×106) 125.7 ± 136.9 103.6 ± 116.2 0.48
SEMG+ (%) 69.9 ± 19.4 78.8 ± 16.6 0.21
Total SEMG+ count (×106) 130.2 ± 103.8 126.9 ± 149.7 0.34
Total SEMG− count (×106) 73.4 ± 114.5 36.7 ± 60.3 0.06
SP + IUI: patients whose wives achieved pregnancy either spontaneously (SP) or through IUI; IVF+ ICSI: patients whose wives achieved pregnancy through IVF or ICSI
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it is likely that even such a couple should consider early
step-up using the data of total SEMG− count. More data
must be collected to evidence this hypothesis and to deter-
mine any cut-off value. In the future, SEMGs bound to
sperm may be used to determine whether IUI, IVF, or ICSI
treatment should be administered promptly, without wait-
ing for spontaneous pregnancy, in case of couples who de-
sire to have their own child.
Conclusions
Regarding the partner of patient pregnancy subgroup, the
total SEMG− count tended to be high in patients whose
partners had spontaneous pregnancy or who underwent
IUI treatment, compared with partners of patients who
used other treatments. This result suggests that SEMGs
inhibit ectopic capacitation before sperm reach the
fertilization site and that the number of total SEMG-
unbound sperm is a parameter directly linked to the possi-
bility of in vivo fertilization. It is possible that total SEMG−
count might be a tool for determining whether IUI, spon-
taneous conception, IVF, or ICSI should be used for the
partners’ treatment of ART. It is necessary to perform fur-
ther large-scale studies to establish the diagnostic certainty
of SEMGs bound to spermatozoa.
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